ENDRA Life Sciences (NDRA) Equity Ratio (2016 - 2026)

ENDRA Life Sciences has disclosed Equity Ratio across 11 years of filings, most recently posting 0.52 for Q1 2026.

• In Q1 2026, Equity Ratio fell 5.99% year-over-year to 0.52; the TTM figure through Mar 2026 stood at 0.52 (down 5.99% YoY), while the FY2025 annual figure was 0.59, up 1.98% from the prior year.
• Equity Ratio fell to 0.52 in Q1 2026, from 0.59 in the prior quarter.
• Over the last five years, Equity Ratio for NDRA reached as high as 0.87 in Q2 2022 and fell as low as 0.09 in Q3 2025.
• The 5-year median for Equity Ratio is 0.73 (2024), against an average of 0.68.
• Annual changes were most pronounced in 2024 — Equity Ratio climbed 15.33% — and 2025, when it slumped 88.93%.
• A 5-year view of Equity Ratio shows it stood at 0.78 in 2022, then gained by 7.85% to 0.84 in 2023, then plunged by 31.37% to 0.58 in 2024, then advanced by 1.98% to 0.59 in 2025, then retreated by 11.38% to 0.52 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.52, 0.59, and 0.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.